Purpose: The possible mechanism of Xiyanping injection treatment COVID-19 is discussed through the network pharmacology.
Methods: Obtaining the chemical structure of Xiyanping injection through the patent application and obtaining control compounds I, II, III, IV, V, Yanhuning injection (VI, VII), Chuanhuning injection (VIII, IX), 10 compounds were analyzed by D3Targets-2019-nCoV. The human anti-COVID-19 gene in COVID-19 DisGeNET was intersected with the CTD Andrographolide target gene and then combined with D3Targets-2019-nCoV, resulting in 93 genes, using the Venny 2.1 platform. The PPI network was constructed by the String platform and Cytoscape 3.8.2 platform. The GO, KEGG, and tissue of the target were analyzed using the Metascape platform and DAVID platform. The gene expression in the respiratory system was analyzed using the ePlant platform. The CB-Dock is used for the docking verification and degree values of the first 20 genes.
Results: Finally, 1599 GO and 291 KEGG results were obtained. GO is mostly associated with the cell stress response to chemicals, the cell response to oxidative stress, and the cell response to reactive oxygen species. In total, 218 KEGG pathway concentrations were related to infection and other diseases and 73 signaling pathways mostly related to inflammation and immune pathways, such as TNF signaling pathway and MAPK signaling pathway. The molecular docking results show that Xiyanping injection, compound III, has a good docking relationship with 20 target proteins such as HSP90AA1. Tissue has 22 genes that are pooled in the lungs.
Conclusion: Xiyanping injection may inhibit the release of various inflammatory factors by inhibiting intracellular pathways such as MAPK and TNF. It acts on protein targets such as HSP90AA1 and plays a potential therapeutic role in COVID-19. Thus, compound III may be treated as a potential new drug for the treatment of COVID-19 and the Xiyanping injection may treat patients with COVID-19 infection.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9271007 | PMC |
http://dx.doi.org/10.1155/2022/9152201 | DOI Listing |
Zhongguo Zhong Yao Za Zhi
September 2024
Department of Pediatrics, Affiliated Hospital of Chengdu University of Traditional Chinese Medicine Chengdu 610072, China.
Based on network Meta-analysis, we compared the effects of four traditional Chinese medicine(TCM) injections combined with conventional treatment on clinical total effective rate, recovery time of body temperature, cough disappearance time, lung rale disappearance time, wheezing relief time, and lung shadow disappearance time of bronchopneumonia in children and evaluated the safety of the four TCM injections in the treatment of bronchopneumonia in children, so as to provide an evidence-based basis for the clinical use of medication for bronchopneumonia in children. Computer retrieval was performed on CNKI, Wanfang, VIP, SinoMed, PubMed, EMbase, Web of Science, and Cochrane Library databases for randomized controlled trial(RCT) on the treatment of bronchopneumonia in children with TCM injections. The search time limit was from the establishment of each database to 2 January 2024.
View Article and Find Full Text PDFFront Pharmacol
June 2024
Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing, China.
Front Pediatr
June 2024
College of Clinical Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu, China.
Zhongguo Dang Dai Er Ke Za Zhi
November 2023
Department of Respiratory Medicine, Jiangxi Provincial Children's Hospital, Nanchang 330000, China.
Objectives: To study the efficacy and safety of Xiyanping injection through intramuscular injection for the treatment of acute bronchitis in children.
Methods: A prospective study was conducted from December 2021 to October 2022, including 78 children with acute bronchitis from three hospitals using a multicenter, randomized, parallel-controlled design. The participants were divided into a test group (conventional treatment plus Xiyanping injection; =36) and a control group (conventional treatment alone; =37) in a 1:1 ratio.
Medicine (Baltimore)
August 2023
Department of Clinical Chinese Pharmacy, School of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing, China.
Background: Coronavirus disease 2019 (COVID-19) has spread rapidly worldwide, leading to a pandemic. In China, Xiyanping injection (XYP) has been recommended as a drug for COVID-19 treatment in the Guideline on Diagnosis and Treatment of COVID-19 by the National Health Commission of the People Republic of China and National Administration of Traditional Chinese Medicine (Trial eighth Edition). However, the relevant mechanisms at the molecular-level need to be further elucidated.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!